BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Drug Development

  Eleven Bio Announces Investigational New Drug Application Submission To Initiate Clinical Trials Of EBI-031 For Ocular Diseases

  June 13, 2016

   · 

  3 min read
• Biotech Beach

  PancreaCell Unveils Total Pancreas Regeneration Device Ahead Of ADA

  June 13, 2016

   · 

  4 min read
• 3M Canada Funds Personalized Medicine At London’s Hospitals

  June 13, 2016

   · 

  4 min read
• Drug Development

  REPEAT/Janssen-Cilag International NV’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes

  June 13, 2016

   · 

  11 min read
• Drug Development

  Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase III Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia

  June 13, 2016

   · 

  10 min read
• Bio NC

  Assisi Animal Health Reveals 4 Causes Of Inflammation In Cats

  June 13, 2016

   · 

  2 min read
• Drug Development

  Merck & Co. An Pfizer Announce Two Pivotal Phase III Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes

  June 13, 2016

   · 

  18 min read
• Drug Development

  AstraZeneca PLC Presents New Data From Multiple Studies On The Effect Of BYDUREON On Glucose Fluctuations In Patients With Type 2 Diabetes

  June 13, 2016

   · 

  12 min read
• Pharm Country

  VeroScience Continues To Explore Clinical Benefits Of Circadian Neuroendocrine Resetting Therapy With Six Papers Presented At 2016 American Diabetes Association Scientific Sessions June 10-14

  June 13, 2016

   · 

  5 min read
• Drug Development

  Janssen-Cilag International NV’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes

  June 13, 2016

   · 

  11 min read